Tandem Diabetes Care, Inc.: FDA filings under this applicant name
FDA lists 24 510(k) clearances under 2 spellings of the applicant name “Tandem Diabetes Care, Inc.” (first 2011, latest 2026), plus 2 PMA and 2 De Novo decisions, across 8 product codes in 2 review panels. Median 510(k) review time under this name: 88 days. Since 2017 the median was 74 days, against 189 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 0 | — |
| 2013 | 1 | 203 |
| 2014 | 2 | 122 |
| 2015 | 1 | 65 |
| 2016 | 3 | 142 |
| 2017 | 0 | — |
| 2018 | 0 | — |
| 2019 | 0 | — |
| 2020 | 3 | 73 |
| 2021 | 0 | — |
| 2022 | 1 | 469 |
| 2023 | 4 | 87 |
| 2024 | 2 | 73 |
| 2025 | 5 | 68 |
| 2026 | 1 | 73 |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Tandem Diabetes Care, Inc. took a median 74 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 189 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| QFG | Alternate Controller Enabled Insulin Infusion Pump | 10 | 9 |
| LZG | Pump, Infusion, Insulin | 7 | 7 |
| QJI | Interoperable Automated Glycemic Controller | 6 | 5 |
| FPA | Set, Administration, Intravascular | 1 | 1 |
| OUG | Medical Device Data System | 1 | 1 |
| OYC | Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor | 1 | 0 |
| OZO | Automated Insulin Dosing , Threshold Suspend | 1 | 0 |
| QJS | Interoperable Automated Glycemic Controller, Insulin Suspend | 1 | 1 |
Review panels
- Clinical Chemistry (26)
- General Hospital (2)
Most recent Tandem Diabetes Care, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K260429 | Control-IQ+ technology | QJI | 2026-04-24 | 73 |
| K253074 | Tandem Mobi insulin pump with interoperable technology | QFG | 2025-11-06 | 44 |
| K250792 | t:slim X2 insulin pump with interoperable technology | QFG | 2025-09-24 | 194 |
| K251854 | SteadiSet infusion set | FPA | 2025-08-06 | 50 |
| K250798 | Control-IQ+ technology | QJI | 2025-05-21 | 68 |
| K243823 | Control-IQ+ technology | QJI | 2025-02-24 | 74 |
| K241078 | Tandem Mobi Insulin Pump with interoperable technology | QFG | 2024-07-26 | 98 |
| K240309 | Tandem Mobi insulin pump with interoperable technology | QFG | 2024-03-21 | 48 |
| K232382 | Control-IQ Technology | QJI | 2023-11-03 | 87 |
| K232380 | t:slim X2 Insulin Pump with Interoperable Technology | QFG | 2023-11-03 | 87 |
14 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| DEN190034 | De Novo | Interoperable Automated Glycemic Controller | 2019-12-13 |
| DEN180058 | De Novo | Alternate Controller Enabled Insulin Infusion Pump | 2019-02-14 |
| P180008 | PMA | t:slim X2 Insulin Pump with Basal-IQ Technology | 2018-06-21 |
| P140015 | PMA | T:SLIM G4 INSULIN PUMP WITH DEXCOM G4 PLATINUM CGM | 2015-09-08 |
Recalls
15 product recalls in 13 recall events; 12 initiated in the last five years. Most recent: 2026-09-23.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Tandem Diabetes Care, Inc. is the lead sponsor of 17 device studies on ClinicalTrials.gov (1 active or recruiting). Most recent:
- NCT07211126: The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France (Recruiting, started 2026-03-03)
- NCT07325461: Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes (Completed, started 2026-02-18)
- NCT06834568: Tandem Freedom - Feasibility Trial 2 (Completed, started 2025-03-24)
- NCT06717451: PS230005 Control-IQ 1.5 Post-Approval Study (Completed, started 2025-01-30)
- NCT05973422: Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 Diabetes (Unknown, started 2024-05-31)
SEC filings
TANDEM DIABETES CARE INC (TNDM): EDGAR filings, CIK 1438133. An SEC registrant with the same name, matched by name only.
Related HCPCS codes
HCPCS Level II codes whose descriptors match the device names of the product codes filed under Tandem Diabetes Care, Inc. (a text match, not an official crosswalk):
- A4220 — Refill kit for implantable infusion pump (via LZG)
- E0785 — Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement (via OYC)
- E0786 — Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) (via LZG)
FDA spellings included
FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Tandem Diabetes Care, Inc. (27)
- Tandem Diabetes Care (1)
Other FDA applicant names starting with the same word
FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.
- Tandem Medical, Inc. (2 510(k)s)
- Tandem Scanning Corp. (1 510(k)s)
Frequently asked questions
How many FDA 510(k) clearances are listed under Tandem Diabetes Care, Inc.?
FDA lists 24 510(k) clearances under 2 spellings of the applicant name “Tandem Diabetes Care, Inc.” (first 2011, latest 2026), plus 2 PMA and 2 De Novo decisions, across 8 product codes in 2 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Tandem Diabetes Care, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Tandem Diabetes Care, Inc. is 88 days. Since 2017: 74 days, versus 189 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Tandem Diabetes Care, Inc.?
The most frequent FDA product codes under this applicant name are QFG (Alternate Controller Enabled Insulin Infusion Pump, 10); LZG (Pump, Infusion, Insulin, 7); QJI (Interoperable Automated Glycemic Controller, 6).
Next steps
- See all 24 Tandem Diabetes Care, Inc. clearances with predicates and recalls
- Run predicate analysis for product code QFG, Tandem Diabetes Care, Inc.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.